+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market - Global Forecast 2026-2032- Product Image
Myasthenia Gravis Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Myasthenia Gravis Treatment Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674103
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Myasthenia Gravis Treatment Market is projected to reach USD 1.71 Billion in 2026. It is expected to continue growing at a CAGR of 7.88%, reaching USD 2.71 Billion by 2032.

Myasthenia gravis treatment is moving from broad immunosuppression toward targeted, biomarker-informed care for a chronic autoimmune neuromuscular disorder that causes fluctuating skeletal muscle weakness, most often involving ocular, bulbar, limb, and respiratory muscles. Standard therapies such as acetylcholinesterase inhibitors, corticosteroids, steroid-sparing immunosuppressants, thymectomy, intravenous immunoglobulin, and plasma exchange remain important, especially for acute exacerbations and generalized myasthenia gravis.

The treatment landscape is being reshaped by U.S. FDA- and EMA-reviewed biologics that address complement activation and neonatal Fc receptor pathways. Eculizumab, ravulizumab, efgartigimod, rozanolixizumab, and zilucoplan have expanded options for acetylcholine receptor antibody-positive disease and, in selected indications, broader antibody-defined populations. These advances are increasing demand for earlier diagnosis, antibody testing, specialty neurology access, payer evidence, and long-term safety monitoring.

Transformative Shifts in the Treatment Landscape

The most important shift in the myasthenia gravis treatment landscape is the transition from symptom control to disease-modifying immune modulation. Complement C5 inhibition and FcRn blockade have demonstrated clinically meaningful improvements in validated endpoints such as Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores, supporting more personalized treatment sequencing for generalized myasthenia gravis.

Healthcare systems are also shifting from episodic rescue care to proactive management of chronic autoimmune neuromuscular disease. Specialty infusion networks, subcutaneous and self-administration options, real-world evidence programs, and patient-reported outcome tracking are becoming competitive differentiators. At the same time, high-cost biologics are intensifying payer scrutiny, making comparative effectiveness, durability of response, relapse prevention, corticosteroid reduction, and quality-of-life evidence central to market access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant across the myasthenia gravis treatment value chain, particularly in earlier recognition, patient stratification, trial optimization, and pharmacovigilance. Machine learning applied to claims data, electronic health records, neurology notes, and laboratory patterns can help identify underdiagnosed patients and predict risk of exacerbation, while natural language processing can extract weakness patterns, dysphagia, diplopia, ventilatory support, and rescue therapy events from unstructured clinical documentation.

AI is also improving clinical development efficiency by supporting site selection, protocol feasibility, synthetic control exploration, patient-reported outcome analysis, and adverse-event signal detection. However, regulated clinical decision-making still requires physician oversight, transparent validation, bias testing, explainable models, and compliance with privacy frameworks such as HIPAA and GDPR. Leaders that combine AI with clinically curated datasets will be better positioned to generate evidence that clinicians, regulators, and payers trust.

Key Regional Insights

North America remains a leading region for myasthenia gravis treatment adoption due to specialty neurology infrastructure, early biologic approvals, mature payer systems, and strong clinical trial participation. The United States anchors demand through rapid uptake of complement inhibitors and FcRn inhibitors, while Canada emphasizes evidence-based reimbursement, provincial access pathways, and specialist-led treatment protocols for generalized myasthenia gravis.

Europe is characterized by EMA authorization, national health technology assessment, and increasing emphasis on cost-effectiveness, with Germany, France, Italy, Spain, and the United Kingdom shaping access models through clinical benefit assessment, pricing negotiation, and real-world evidence requirements. Asia-Pacific is expanding as Japan, China, Australia, South Korea, and India improve antibody testing, diagnosis, rare disease pathways, and specialist capacity. Latin America shows rising clinical need through Brazil and Mexico, but access varies between public and private channels. The Middle East, led by high-investment tertiary care systems, is strengthening access to advanced neurology therapies, while Africa continues to face constraints related to diagnostic availability, specialist density, reimbursement, and supply chain reliability.

Key Group Insights

The G7 accounts for a major portion of advanced myasthenia gravis treatment adoption because its members combine specialty care networks, regulatory maturity, clinical trial participation, and reimbursement capacity for rare and specialty neurology therapies. The European Union plays a central role through centralized medicine authorization and country-level pricing negotiations, while NATO markets overlap substantially with higher-income healthcare systems that fund advanced immunology and neuromuscular disease treatments.

BRICS countries represent a long-term growth engine for myasthenia gravis treatment access, led by China, India, and Brazil, where rising diagnosis rates, healthcare investment, and expanding specialty care are increasing treated patient visibility. ASEAN markets are improving access through specialist hospital networks and public-sector modernization, although reimbursement and diagnostic availability remain heterogeneous. GCC countries benefit from centralized purchasing, tertiary care investment, and national strategies for specialty medicine access, supporting adoption of advanced therapies for severe generalized myasthenia gravis.

Key Country Insights

The United States leads in clinical innovation and advanced therapy adoption, supported by FDA approvals, specialty pharmacies, neuromuscular centers, and real-world evidence generation. Canada follows a structured reimbursement approach, while Mexico and Brazil are growing through private-sector access, public specialty programs, and increasing neurologist awareness. The United Kingdom, Germany, France, Italy, and Spain are shaped by national assessment bodies that prioritize clinical benefit, budget impact, treatment sequencing, and real-world outcomes. Russia remains relevant in regional access planning but faces complexity linked to procurement, reimbursement, and geopolitical factors.

China, Japan, India, Australia, and South Korea are central to Asia-Pacific expansion in myasthenia gravis treatment. Japan has strong rare disease and neurology infrastructure, China is scaling biologic access through regulatory modernization and hospital-based specialty care, and India offers large unmet need with affordability and diagnostic constraints. Australia and South Korea combine specialist capacity with evidence-based reimbursement and high-quality tertiary care, supporting broader use of advanced therapies where clinical and payer criteria are met.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate sustained symptom control, reduced exacerbations, steroid-sparing effects, improved daily functioning, and lower rescue therapy dependence. Payers are increasingly asking whether premium biologics reduce hospitalizations, intensive care use, plasma exchange, intravenous immunoglobulin reliance, and long-term corticosteroid burden, so real-world evidence should be built into launch and lifecycle plans.

Organizations should also invest in antibody testing pathways, physician education, patient support services, and differentiated administration models, including infusion, subcutaneous, and self-administration options where approved. Strategic partnerships with neuromuscular centers, specialty pharmacies, patient registries, and data platforms can accelerate diagnosis and improve adherence. For emerging markets, tiered access strategies, local evidence generation, diagnostic capacity building, and health-system partnerships will be essential to responsible growth.

Research Methodology

This executive summary is informed by triangulation of public regulatory records, peer-reviewed neurology literature, clinical trial registries, treatment guidelines, health technology assessment outputs, and published evidence on approved therapeutic classes. Emphasis was placed on validated clinical endpoints, antibody-defined populations, mechanism-of-action differentiation, regional access dynamics, and observable shifts in care delivery.

The research approach applies secondary data review, market structure analysis, therapy-class mapping, regional comparison, and expert interpretation of commercialization factors. Data points were assessed for consistency across authoritative sources such as FDA, EMA, clinical guideline bodies, clinical trial publications, and health technology assessment reports. Forward-looking insights are framed as evidence-based interpretations of current treatment and access trends rather than unsupported forecasts.

Conclusion

Myasthenia gravis treatment is entering a more targeted and competitive era, with complement inhibitors and FcRn inhibitors redefining expectations for generalized disease management. Conventional therapy remains foundational, but the center of gravity is shifting toward precision immunology, validated outcome measurement, individualized sequencing, and patient-centered care models.

Success in the global myasthenia gravis treatment landscape will depend on more than clinical efficacy. Leaders must demonstrate long-term value, streamline diagnosis, expand antibody testing, manage biologic access, and generate credible real-world evidence across diverse healthcare systems. Organizations that integrate science, data, affordability, and patient support will be best positioned as care for myasthenia gravis continues to evolve.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Myasthenia Gravis Treatment Market, by Treatment Class
7.1. Introduction
7.2. Acetylcholinesterase Inhibitors
7.3. Immunosuppressants
7.3.1. Corticosteroids
7.3.2. Nonsteroidal Immunosuppressants
7.4. Intravenous Immunoglobulin
7.5. Monoclonal Antibodies
7.6. Plasma Exchange
8. Myasthenia Gravis Treatment Market, by Disease Type
8.1. Introduction
8.2. Generalized Myasthenia Gravis
8.3. Ocular Myasthenia Gravis
8.4. Juvenile-Onset Myasthenia Gravis
9. Myasthenia Gravis Treatment Market, by Administration Route
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Myasthenia Gravis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Myasthenia Gravis Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Myasthenia Gravis Treatment Market, by Region
12.1. Europe
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Myasthenia Gravis Treatment Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. Myasthenia Gravis Treatment Market, by Country
14.1. United States
14.2. China
14.3. Germany
14.4. United Kingdom
14.5. Japan
14.6. India
14.7. Canada
14.8. France
14.9. Brazil
14.10. Mexico
14.11. Italy
14.12. Russia
14.13. Australia
14.14. Spain
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca PLC
16.2. argenx SE
16.3. UCB S.A.
16.4. Johnson & Johnson Services Inc.
16.5. Novartis AG
16.6. Grifols, S.A.
16.7. Takeda Pharmaceutical Company Limited
16.8. F. Hoffmann-La Roche Ltd.
16.9. Bausch Health Companies Inc.
16.10. Catalyst Pharmaceuticals, Inc.
16.11. Dr. Reddy’s Laboratories Limited
16.12. Teva Pharmaceutical Industries Ltd.
16.13. Amgen Inc.
16.14. Arcellx, Inc.
16.15. Asahi Kasei Medical Co., Ltd.
16.16. Hikma Pharmaceuticals PLC
16.17. Immunovant Sciences GmbH
16.18. Merck KGaA
16.19. Regeneron Pharmaceuticals, Inc.
16.20. Terumo BCT, Inc.
List of Figures
FIGURE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACETYLCHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NONSTEROIDAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GENERALIZED MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL OCULAR MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL JUVENILE-ONSET MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 68. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 69. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 70. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 71. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 72. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 96. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 97. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 98. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 99. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 100. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 111. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 112. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 113. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 114. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 118. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 119. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 120. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 121. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 132. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 133. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 134. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 135. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 139. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 140. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 141. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 142. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 146. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 147. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 148. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 149. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 153. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 154. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 155. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 156. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 157. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 160. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 161. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 162. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 163. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 164. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 168. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 169. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 170. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 171. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 175. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 176. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 178. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 181. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 182. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 183. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 184. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 185. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 189. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 190. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 191. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 192. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 193. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 195. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 196. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 197. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 198. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 199. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 203. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 204. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 205. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 206. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 210. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 211. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 212. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 213. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 217. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 218. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 219. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 220. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 224. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 225. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 226. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 227. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 233. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 234. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 245. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 246. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 247. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 248. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 252. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2017-2032 (USD MILLION)
TABLE 253. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 254. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 255. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 258. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AstraZeneca PLC
  • argenx SE
  • UCB S.A.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Bausch Health Companies Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Arcellx, Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Immunovant Sciences GmbH
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Terumo BCT, Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.71 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Myasthenia Gravis Treatment Market Report 2026 - Product Image

Myasthenia Gravis Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Myasthenia Gravis Therapeutics Market Outlook 2026-2034: Market Share and Growth Analysis by Treatment, Route of Administration, Drug Class, End-User - Product Image

Myasthenia Gravis Therapeutics Market Outlook 2026-2034: Market Share and Growth Analysis by Treatment, Route of Administration, Drug Class, End-User

  • Report
  • 160 Pages
  • Global
From
Myasthenia Gravis Drugs - Global Strategic Business Report - Product Image

Myasthenia Gravis Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Myasthenia Gravis Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Myasthenia Gravis Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 111 Pages
  • Global
From

About the Myasthenia Gravis Drug Market

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. MG is treated with a variety of drugs, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Anticholinesterase drugs, such as pyridostigmine, are used to increase the availability of acetylcholine at the neuromuscular junction, thereby improving muscle strength. Immunosuppressants, such as azathioprine and cyclosporine, are used to reduce the production of antibodies that attack the neuromuscular junction. Immunomodulators, such as mycophenolate mofetil, are used to modulate the immune system and reduce the production of antibodies. The Myasthenia Gravis Drug market is a subset of the Central Nervous System Drugs market. It is composed of a variety of drugs used to treat MG, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Companies in the Myasthenia Gravis Drug market include Merck, Pfizer, Novartis, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.